Biosynex SA
Paris Stock Exchange ALBIO.PA
Biosynex SA Goodwill for the year ending December 31, 2023: USD 101.04 M
-
Biosynex SA Goodwill for the year ending December 31, 2022 was USD 65.17 M, a 23.81% change year over year.
-
Biosynex SA Goodwill for the year ending December 31, 2021 was USD 52.64 M, a 47.20% change year over year.
-
Biosynex SA Goodwill for the year ending December 31, 2020 was USD 35.76 M, a 15.50% change year over year.
-
Biosynex SA Goodwill for the year ending December 31, 2019 was USD 30.96 M, a 18.52% change year over year.
| Date | Goodwill | Total Assets | Current Liabilities | Total Non-Current Liabilities |
|---|
Don’t Miss A Beat
| CEO | Mr. Larry Abensur |
| IPO Date | March 28, 2011 |
| Location | France |
| Headquarters | 22 Boulevard Sébastien Brant |
| Employees | 515 |
| Sector | Consumers Staples |
| Industries | |
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers a range of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women's health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France.
Past 5 years
USD 26.53
StockViz Staff
February 7, 2025
Any question? Send us an email